RE:RE:A better deal is HIP via CMED Read everything at:
https://www.stockwatch.com/News/Search.aspx?wire=0&symbolchanges=Y&symbol=HIP®ion=C
https://www.stockwatch.com/News/Search.aspx?wire=0&symbolchanges=Y&symbol=CMED®ion=C
And specifically
| 2018-01-03 07:11 | CMED | CanniMed Therapeutics Inc | 24.15 | In the News | Globe says Newstrike CEO betting on focused marketing |
| 2018-01-02 07:17 | CMED | CanniMed Therapeutics Inc | 22.55 | News Release | CanniMed signs weed supply deal with Newstrike unit |
| 2017-11-17 16:54 | CMED | CanniMed Therapeutics Inc | 19.32 | News Release | CanniMed to acquire Newstrike, Up Cannabis |
| 2017-11-17 07:50 | CMED | CanniMed Therapeutics Inc | 19.50 | In the News | FP/CP say Newstrike in merger talks with CanniMed |
| 2017-09-11 07:13 | CMED | CanniMed Therapeutics Inc | 8.85 | SEDAR MD & A | SEDAR MD & A |
And specifically
"On September 20, 2017, the CanniMed Board approved the terms of a convertible loan financing for Newstrike with a view to ensure the continued exclusivity of discussions beyond September 29, 2017, and on that day, the Newstrike Exclusivity Period was further extended to October 31, 2017. On September 29, 2017, a CanniMed subsidiary subscribed for a convertible debenture in the principal amount of $4,000,000 and 10,958,904 common share purchase warrants exercisable at $0.42 per common share (the “Newstrike Debenture Financing”). On September 20, 2017, the CanniMed Board formed a committee of directors (the “First Committee”) consisting of Robert Duguid, Donald Ching, Richard Hoyt and Dwayne Lashyn, with the mandate of the First Committee being to consider potential strategies and opportunities for merger and acquisition activities by CanniMed and to make recommendations to the CanniMed Board in relation to such strategies and opportunities. On September 27, 2017, the CanniMed Board clarified, with Doug Banzet, Robert Duguid and Dwayne Lashyn abstaining, that the mandate of the First Committee did not extend to the initiation by CanniMed of a strategic sale process, including potential change of control transactions. Following the completion of the Newstrike Debenture Financing, CanniMed and Newstrike continued discussions with respect to, among other things, the potential for business and commercial arrangements between the parties, including with respect to the supply and storage of cannabis and commercial discussions with respect to a possible business combination."
In the December SEDAR Director Circular filing by CMED.
https://www.stockwatch.com/News/Sedardoc.pdf?docid=3961358
| 2017-12-11 08:24 | CMED | CanniMed Therapeutics Inc | 19.93 | SEDAR Directors' Circular | SEDAR Directors' Circular |
There are 224 references to Newstrike that ALL investors and traders should be familiar with.
These are available at Stockwatch (with account) or free on SEDAR.CA (where all corporate filings are done).